Previous 10 | Next 10 |
Vanda Pharmaceuticals ( NASDAQ: VNDA ) is scheduled to announce Q3 earnings results on Wednesday, November 2nd, after market close. The consensus EPS Estimate is $0.09 (-35.7% Y/Y) and the consensus Revenue Estimate is $71M (+1.3% Y/Y). Over the last 3 months, Revenue ...
Vanda Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022 PR Newswire Conference Call and Webcast to Follow WASHINGTON , Oct. 26, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announc...
Summary From the commercialization front, Vanda Pharmaceuticals is taking prudent steps to boost Hetlioz and Fanapt sales. The company recently planted long-term growth via the OliPas partnership for ASO development. Additionally, Vanda is advancing VPO-227 with UCSF for its f...
Commercial-stage biotech Vanda Pharmaceuticals ( NASDAQ: VNDA ) announced Friday that the FDA issued Orphan Drug Designation for VPO-227, an experimental therapy for cholera. Despite the low incidence of cholera in the U.S., the infection is a global concern that leads to ...
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera PR Newswire WASHINGTON , Oct. 21, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA ) today announced the U...
Summary Vanda Pharmaceuticals is a stellar growth stock trading near its cash position. Despite the latest revenue trend aberration, Vanda is still set to post significant sales increase for Fiscal 2022. There are several growth catalysts like the recent OliPass partnership to...
Vanda Pharmaceuticals ( NASDAQ: VNDA ) and South Korea-based biotech OliPass on Thursday said they had entered into a research and development collaboration deal to make antisense oligonucleotide (ASO) therapeutics. ASOs are small pieces of DNA or RNA that can bind to spec...
Vanda Pharmaceuticals and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics PR Newswire WASHINGTON , Sept. 29, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and OliPass Corporation (OliPass) ...
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference PR Newswire WASHINGTON , Sept. 8, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the company will participate in...
VANDA PHARMACEUTICALS ANNOUNCES NOTICE OF OPPORTUNITY FOR AN FDA HEARING ON THE sNDA FOR HETLIOZ® IN JET LAG DISORDER PR Newswire WASHINGTON , Sept. 7, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the notice ...
News, Short Squeeze, Breakout and More Instantly...
Vanda Pharmaceuticals Inc. Company Name:
VNDA Stock Symbol:
NASDAQ Market:
Vanda Pharmaceuticals Inc. Website:
2024-07-17 04:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-11 07:00:07 ET Charles Duncan from Cantor Fitzgerald issued a price target of $11.00 for VNDA on 2024-07-11 06:12:00. The adjusted price target was set to $11.00. At the time of the announcement, VNDA was trading at $5.21. VNDA currently trades -22.96% versus its...
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex PR Newswire WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of ...